Quiz

November 02, 2017
According to a recent study, which therapy is most cost-effective for reducing the risk of skeletal events in breast cancer? -----   A. Denosumab every month B. Zoledronic acid every 3 months C. Denosumab every 3 months | Read More
October 27, 2017
In the highly active antiretroviral therapy era, which secondary malignancy to Kaposi sarcoma has emerged as a new risk for patients? ----- A. Chronic myeloid leukemia B. Chronic lymphocytic leukemia C. Acute lymphocytic leukemia | Read More
October 26, 2017
In the highly active antiretroviral therapy era, which secondary malignancy to Kaposi sarcoma has emerged as a new risk for patients? ----- A. Chronic myeloid leukemia B. Chronic lymphocytic leukemia C. Acute lymphocytic leukemia | Read More